Drug Profile
Tivumecirnon - RAPT Therapeutics
Alternative Names: FLX-475Latest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator FLX Bio
- Developer Hanmi Pharmaceutical; Merck & Co; RAPT Therapeutics
- Class 2 ring heterocyclic compounds; Antineoplastics; Azetidines; Piperidines; Pyrazines; Pyrazoles; Small molecules
- Mechanism of Action CCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cancer; Gastric cancer; Malignant melanoma
Most Recent Events
- 09 Apr 2024 Efficacy data from a phase I/II trial in Cancer released by RAPT Therapeutics
- 03 Nov 2023 Updated safety and efficacy data from the phase I/II trial in Advanced Non-small cell lung cancer released by RAPT Therapeutics
- 17 Oct 2023 Hanmi Pharmaceutical and Merck complete a phase II trial for Gastric cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea (PO, Tablet) (NCT04768686)